167 related articles for article (PubMed ID: 30880197)
1. Immune Microenvironment of Primary and Recurrent Craniopharyngiomas: A Study of the Differences and Clinical Significance.
Lin D; Wang Y; Zhou Z; Lin Z
World Neurosurg; 2019 Jul; 127():e212-e220. PubMed ID: 30880197
[TBL] [Abstract][Full Text] [Related]
2. Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer.
Ojalvo LS; Thompson ED; Wang TL; Meeker AK; Shih IM; Fader AN; Cimino-Mathews A; Emens LA
Hum Pathol; 2018 Apr; 74():135-147. PubMed ID: 29288043
[TBL] [Abstract][Full Text] [Related]
3. Autophagy and immune microenvironment in craniopharyngioma and ameloblastoma.
Karpathiou G; Hamlat M; Dridi M; Forest F; Papoudou-Bai A; Dumollard JM; Peoc'h M
Exp Mol Pathol; 2021 Dec; 123():104712. PubMed ID: 34655574
[TBL] [Abstract][Full Text] [Related]
4. Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma.
Coy S; Rashid R; Lin JR; Du Z; Donson AM; Hankinson TC; Foreman NK; Manley PE; Kieran MW; Reardon DA; Sorger PK; Santagata S
Neuro Oncol; 2018 Jul; 20(8):1101-1112. PubMed ID: 29509940
[TBL] [Abstract][Full Text] [Related]
5. Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes.
Shurell E; Singh AS; Crompton JG; Jensen S; Li Y; Dry S; Nelson S; Chmielowski B; Bernthal N; Federman N; Tumeh P; Eilber FC
Oncotarget; 2016 Sep; 7(39):64300-64308. PubMed ID: 27588404
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability.
Korehisa S; Oki E; Iimori M; Nakaji Y; Shimokawa M; Saeki H; Okano S; Oda Y; Maehara Y
Int J Cancer; 2018 Feb; 142(4):822-832. PubMed ID: 29044503
[TBL] [Abstract][Full Text] [Related]
7. Growth patterns of craniopharyngiomas: clinical analysis of 226 patients.
Pan J; Qi S; Liu Y; Lu Y; Peng J; Zhang X; Xu Y; Huang GL; Fan J
J Neurosurg Pediatr; 2016 Apr; 17(4):418-33. PubMed ID: 26636252
[TBL] [Abstract][Full Text] [Related]
8. A Combination of Positive Tumor HLA-I and Negative PD-L1 Expression Provides an Immune Rejection Mechanism in Bladder Cancer.
Flores-Martín JF; Perea F; Exposito-Ruiz M; Carretero FJ; Rodriguez T; Villamediana M; Ruiz-Cabello F; Garrido F; Cózar-Olmo JM; Aptsiauri N
Ann Surg Oncol; 2019 Aug; 26(8):2631-2639. PubMed ID: 31011905
[TBL] [Abstract][Full Text] [Related]
9. The expression profile of PD-L1 and CD8
Wang PF; Wang TJ; Yang YK; Yao K; Li Z; Li YM; Yan CX
J Neurooncol; 2018 Aug; 139(1):89-95. PubMed ID: 29680903
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 expression and CD8+ infiltration shows heterogeneity in juvenile recurrent respiratory papillomatosis.
Liu T; Greenberg M; Wentland C; Sepe B; Bowe S; Diercks G; Huynh T; Mino-Kenudson M; Schlegel R; Kodack D; Benes C; Engelman J; Hartnick C
Int J Pediatr Otorhinolaryngol; 2017 Apr; 95():133-138. PubMed ID: 28576522
[TBL] [Abstract][Full Text] [Related]
11. Predictive factors for craniopharyngioma recurrence: a systematic review and illustrative case report of a rapid recurrence.
Prieto R; Pascual JM; Subhi-Issa I; Jorquera M; Yus M; Martínez R
World Neurosurg; 2013; 79(5-6):733-49. PubMed ID: 22892136
[TBL] [Abstract][Full Text] [Related]
12. Immune microenvironment and evasion mechanisms in adenoid cystic carcinomas of salivary glands.
Mosconi C; de Arruda JAA; de Farias ACR; Oliveira GAQ; de Paula HM; Fonseca FP; Mesquita RA; Silva TA; Mendonça EF; Batista AC
Oral Oncol; 2019 Jan; 88():95-101. PubMed ID: 30616805
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
Menguy S; Prochazkova-Carlotti M; Beylot-Barry M; Saltel F; Vergier B; Merlio JP; Pham-Ledard A
Am J Surg Pathol; 2018 Mar; 42(3):326-334. PubMed ID: 29112015
[TBL] [Abstract][Full Text] [Related]
14. Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy.
Saigusa S; Toiyama Y; Tanaka K; Inoue Y; Mori K; Ide S; Imaoka H; Kawamura M; Mohri Y; Kusunoki M
Int J Clin Oncol; 2016 Oct; 21(5):946-952. PubMed ID: 26919982
[TBL] [Abstract][Full Text] [Related]
15. Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma.
Liu CQ; Xu J; Zhou ZG; Jin LL; Yu XJ; Xiao G; Lin J; Zhuang SM; Zhang YJ; Zheng L
Br J Cancer; 2018 Jul; 119(1):80-88. PubMed ID: 29921949
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of the programmed death ligand 1 expression in clear cell renal cell carcinoma and correlation with the tumor microenvironment and hypoxia-inducible factor expression.
Tatli Dogan H; Kiran M; Bilgin B; Kiliçarslan A; Sendur MAN; Yalçin B; Ardiçoglu A; Atmaca AF; Gumuskaya B
Diagn Pathol; 2018 Aug; 13(1):60. PubMed ID: 30144808
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
[TBL] [Abstract][Full Text] [Related]
18. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
19. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and VISTA in craniopharyngioma.
Wang Y; Deng J; Wang L; Zhou T; Yang J; Tian Z; Yang J; Chen H; Tang X; Zhao S; Zhou L; Tong A; Xu J
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32958683
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment.
D'Angelo SP; Shoushtari AN; Agaram NP; Kuk D; Qin LX; Carvajal RD; Dickson MA; Gounder M; Keohan ML; Schwartz GK; Tap WD
Hum Pathol; 2015 Mar; 46(3):357-65. PubMed ID: 25540867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]